Want to see SNGX full AI Analyst Report?
SNGX Stock Chart & Stats
$1.44
-$0.10(-2.65%)
At close: 4:00 PM EST
$1.44
-$0.10(-2.65%)
Day’s Range― - ―
52-Week Range$0.28 - $6.23
Previous CloseN/A
Volume55.16K
Average Volume (3M)14.44M
Market Cap
$5.74M
Enterprise Value-$1.56M
Total Cash (Recent Filing)$6.03M
Total Debt (Recent Filing)$330.66K
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 07, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding14,824,174
10 Day Avg. Volume2,307,276
30 Day Avg. Volume14,436,267
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.68
Enterprise Value/Market Cap-0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit741.41
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$1.50Price Target Upside4.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.85
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline Refocus To Orphan AssetShifting resources toward an orphan-designated program (dusquetide for Behçet’s) is a durable strategic move: orphan indications often benefit from accelerated pathways, smaller trial sizes, and premium pricing potential, improving odds of commercial viability versus broad indications over the medium term.
Material Reduction In LeverageSubstantially lower debt and a much-improved debt/equity ratio reduce refinancing pressure and interest burden, enhancing financial flexibility. This durable improvement increases optionality for strategic moves (partnering, M&A) without immediate debt overhang.
Access To Government Biodefense FundingInclusion in BARDA and similar government initiatives indicates structural access to non-dilutive R&D funding and procurement pathways. Durable government demand for medical countermeasures can provide stable program funding and strategic credibility versus purely private funding sources.
Bears Say
Zero Revenue And Heavy Cash BurnPersistent, sizable operating losses and matching negative free cash flow create an ongoing funding requirement. Without commercial revenue, the company must repeatedly access capital markets or grants, diluting shareholders or risking program delays—an enduring constraint on strategy and runway.
Phase 3 HyBryte Halted For FutilityTermination of a pivotal Phase 3 program is a structural setback: it removes a potential near-term approval and revenue driver, shrinks the clinical-stage pipeline, and increases reliance on remaining assets or external transactions to rebuild value, raising long-term execution risk.
Nasdaq Minimum Bid Non-complianceA sustained low share price prompting Nasdaq non-compliance carries durable risks: potential delisting can impair liquidity, limit access to institutional capital, and complicate equity raises or M&A, materially constraining strategic flexibility until resolved.
Soligenix News
SNGX FAQ
What was Soligenix Inc’s price range in the past 12 months?
Soligenix Inc lowest stock price was $0.28 and its highest was $6.23 in the past 12 months.
What is Soligenix Inc’s market cap?
Soligenix Inc’s market cap is $5.74M.
When is Soligenix Inc’s upcoming earnings report date?
Soligenix Inc’s upcoming earnings report date is Aug 07, 2026 which is in 35 days.
How were Soligenix Inc’s earnings last quarter?
Soligenix Inc released its earnings results on May 08, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.28.
Is Soligenix Inc overvalued?
According to Wall Street analysts Soligenix Inc’s price is currently Undervalued.
Does Soligenix Inc pay dividends?
Soligenix Inc does not currently pay dividends.
What is Soligenix Inc’s EPS estimate?
Soligenix Inc’s EPS estimate is -0.16.
How many shares outstanding does Soligenix Inc have?
Soligenix Inc has 14,824,174 shares outstanding.
What happened to Soligenix Inc’s price movement after its last earnings report?
Soligenix Inc reported an EPS of -$0.28 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.87%.
Which hedge fund is a major shareholder of Soligenix Inc?
Currently, no hedge funds are holding shares in SNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Soligenix Inc
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.
SNGX Stock 12 Month Forecast
Average Price Target
$1.50
▲(4.17% Upside)
Technical Analysis
Ownership Overview
0.23% Insiders
0.90% Mutual Funds
<0.01% Other Institutional Investors
98.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---